89848-21-5

Usage

Uses

Used in Hormonal Birth Control:
Norgestrienone is used as a progestin component in combination with estrogen for hormonal birth control. It prevents ovulation and modifies the cervical mucus and endometrium to hinder sperm from reaching the uterus and a fertilized egg from implanting.
Used in Endometriosis Treatment:
Norgestrienone is employed as a treatment for endometriosis, a condition where tissue similar to the lining of the uterus grows outside the uterus, causing pain and heavy bleeding.
Used in Abnormal Menstrual Cycles Treatment:
Norgestrienone is used as a medication to regulate abnormal menstrual cycles, helping to establish a more regular menstrual pattern.
Used in Menopausal Symptoms Management:
Norgestrienone is utilized to alleviate menopausal symptoms, such as hot flashes and vaginal dryness, by providing the necessary hormonal support.
Used in Various Pharmaceutical Forms:
Norgestrienone is available in different forms, including oral tablets, injections, and implants, catering to various patient preferences and medical requirements.

InChI:InChI=1/C22H27N5O2/c1-3-17(2)27-22(29)26(16-23-27)21-7-5-4-6-20(21)25-14-12-24(13-15-25)18-8-10-19(28)11-9-18/h4-11,16-17,28H,3,12-15H2,1-2H3

Upstream product

• 74852-61-2 1-(4-methoxyphenyl)-4-(4-nitrophenyl)-piperazine 
• 74852-62-3 4-[4-(4-methoxy-phenyl)-piperazin-1-yl]-phenylamine 
• 100-00-5 4-chlorobenzonitrile 
• 38212-30-5 4-(4-methoxyphenyl)piperazine 
• 89848-16-8 1-isobutyl-4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one 
• 74853-06-8 phenyl (4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)carbamate 
• 74852-89-4 N-{4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl}hydrazinecarboxamide 
• 74853-07-9 2,4-dihydro-4-[4-[4-(4-methoxyphenyl)-1-piperazinyl ]-phenyl]-3H-1,2,4-triazol-3-one 

Downstream Products

• 89848-53-3 4-[4-(4-{4-[(2R,4S)-2-(2,4-Dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2-isobutyl-2,4-dihydro-[1,2,4]triazol-3-one 
• 1339803-67-6 cis-(2S,4R)-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-isobutyl-3H-1,2,4-triazol-3-one 

Relevant academic research and scientific papers

ITRACONAZOLE ANALOGS AND USE THEREOF

Provided herein are Itraconazole analogs. Also provided herein are methods of inhibition of Hedgehog pathway, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, angiogenesis and treatment of disease with Itraconazole analogs.

Itraconazole Side Chain Analogues: Structure-Activity Relationship Studies for Inhibition of Endothelial Cell Proliferation, Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Glycosylation, and Hedgehog Signaling

Itraconazole is an antifungal drug that was recently found to possess potent antiangiogenic activity and anti-hedgehog (Hh) pathway activity. To search for analogues of itraconazole with greater potency and to understand the structure-activity relationship in both antiangiogenic and Hh targeting activity, 25 itraconazole side chain analogues were synthesized and assayed for inhibition of endothelial cell proliferation and Gli1 transcription in a medulloblastoma (MB) culture. Through this analysis, we have identified analogues with increased potency for inhibiting endothelial cell proliferation and the Hh pathway, as well as VEGFR2 glycosylation that was recently found to be inhibited by itraconazole. An SAR analysis of these activities revealed that potent activity of the analogues against VEGFR2 glycosylation was generally driven by side chains of at least four carbons in composition with branching at the α or β position. SAR trends for targeting the Hh pathway were divergent from those related to HUVEC proliferation or VEGFR2 glycosylation. These results also suggest that modification of the sec-butyl side chain can lead to enhancement of the biological activity of itraconazole.

Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones

A series of novel triazol-3-ones has been synthesized, and their in vitro and in vivo antifungal properties are reported. Traconazole. which displays a pronounced oral activity against vaginal candidosis in rats and against microsporosis in guinea pigs, has been selected for clinical evaluation.